Literature DB >> 2960730

The influence of valence on the functional activities of monoclonal anti-L3T4 antibodies. Discrimination of signaling from other effects.

S Haque1, K Saizawa, J Rojo, C A Janeway.   

Abstract

Anti-L3T4 antibodies have different functional effects on different ligands that activate a cloned, L3T4+ helper T cell line. It is reported here that some of these effects involve positive or negative signaling induced by cross-linking L3T4 molecules, because such effects are not observed using the Fab fragment of anti-L3T4. However, the Fab fragment does inhibit responses to antigen:self class II major histocompatibility complex (MHC) and to anti-T cell receptor monoclonal antibodies directed at a particular V region epitope. The finding that the Fab fragment of anti-L3T4, which does not block binding of anti-T cell receptor V region antibodies and does not negative signal can still block activation by such antibodies suggests an intimate association of L3T4 with the T3: alpha: beta T cell receptor complex. This association may normally be induced by interaction of both structures with antigen:self class II MHC complexes. The data also support the hypothesis that cross-linking the L3T4 molecule in the absence of engagement of the T3: alpha: beta complex generates negative or inhibitory signals. Thus, L3T4 plays a central role in the process of class II MHC-restricted T cell antigen recognition and activation.

Mesh:

Substances:

Year:  1987        PMID: 2960730

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues.

Authors:  Aaron J Martin; Matthew Clark; Gregory Gojanovich; Fatima Manzoor; Keith Miller; Douglas E Kline; Y Maurice Morillon; Bo Wang; Roland Tisch
Journal:  JCI Insight       Date:  2016-10-20

2.  Physical association of CD4 and the T-cell receptor can be induced by anti-T-cell receptor antibodies.

Authors:  J M Rojo; K Saizawa; C A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

Review 3.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

4.  ImmunoPET Imaging of Murine CD4+ T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging.

Authors:  Amanda C Freise; Kirstin A Zettlitz; Felix B Salazar; Xiang Lu; Richard Tavaré; Anna M Wu
Journal:  Mol Imaging Biol       Date:  2017-08       Impact factor: 3.488

5.  Murine T-cell response to native and recombinant protein antigens of Rickettsia tsutsugamushi.

Authors:  C J Hickman; C K Stover; S W Joseph; E V Oaks
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

6.  Administration of purified anti-L3T4 monoclonal antibody impairs the resistance of mice to Listeria monocytogenes infection.

Authors:  C J Czuprynski; J F Brown; K M Young; A J Cooley
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

7.  Cross-linking of CD4 in a TCR/CD3-juxtaposed inhibitory state: a pFRET study.

Authors:  G Szabó; J L Weaver; P S Pine; P E Rao; A Aszalos
Journal:  Biophys J       Date:  1995-03       Impact factor: 4.033

8.  Role of CD4 in thymocyte selection and maturation.

Authors:  J C Zuñiga-Pflücker; S A McCarthy; M Weston; D L Longo; A Singer; A M Kruisbeek
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

Review 9.  Human immunodeficiency virus type 1-associated CD4 downmodulation.

Authors:  R Geleziunas; S Bour; M A Wainberg
Journal:  Adv Virus Res       Date:  1994       Impact factor: 9.937

10.  Single-Domain Antibodies for Targeting, Detection, and In Vivo Imaging of Human CD4+ Cells.

Authors:  Bjoern Traenkle; Philipp D Kaiser; Stefania Pezzana; Jennifer Richardson; Marius Gramlich; Teresa R Wagner; Dominik Seyfried; Melissa Weldle; Stefanie Holz; Yana Parfyonova; Stefan Nueske; Armin M Scholz; Anne Zeck; Meike Jakobi; Nicole Schneiderhan-Marra; Martin Schaller; Andreas Maurer; Cécile Gouttefangeas; Manfred Kneilling; Bernd J Pichler; Dominik Sonanini; Ulrich Rothbauer
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.